$18.490
-1.439 (-7.78%)收盤時
NVCT 資訊
NVCT 事件
Nuvectis Reports Positive Data for NXP200 with 40% Objective Response Rate in Brain Tumor Patients
Nuvectis announced positive, expanded data from the Phase 1b study for NXP200, a second-generation, paradox-breaker BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas, presented at the 2026 European Society for Medical Oncology Congress in Madrid. As of the May 4 cutoff, 27 efficacy-evaluable patients were treated with NXP200 monotherapy, including 20 with high-grade glioma and 7 with low-grade glioma. Treatment with NXP200 resulted in an objective response rate of 40.0% in the high-grade glioma cohort, including 3 complete responses, and 42.9%, including one confirmed complete response, in the low-grade glioma cohort. Deep responses, greater than 80% tumor burden reduction, were achieved in 87.5% of responders with high-grade glioma and 66.7% of responders with low-grade glioma. Among the three patients previously treated with a BRAF inhibitor, two achieved a partial response and one had stable disease. In high-grade glioma, the median duration of response was 6.97 months and the median overall survival was 17.15 months. Among 28 safety-evaluable patients, 14.3% experienced a Grade 3 or higher treatment-related adverse event, and no treatment-related adverse event resulted in treatment discontinuation or death. The study is being conducted by Haisco Pharmaceutical Group in China, and in June, Nuvectis in-licensed exclusive worldwide, ex-Greater China rights to NXP200 from Haisco. "The rate and durability of the responses reported with single-agent NXP200 in patients with recurrent or progressive gliomas are very encouraging," said Ron Bentsur, chairman and CEO.
Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation
Nuvectis Pharma announced that NXP200 has been granted Breakthrough Therapy Designation, BTD, for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China's Center for Drug Evaluation, CDE. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We congratulate our partner Haisco for achieving this significant regulatory milestone, which is further testament to its tremendous strategic and operational capabilities. The CDE's granting of Breakthrough Therapy Designation underscores the compelling clinical activity observed to date with NXP200 in patients with recurrent or progressive BRAF V600-mutant high-grade glioma. In parallel, we continue to advance NXP200 toward a U.S. IND submission in the fourth quarter of 2026."
Nuvectis Pharma Files $200M Mixed Securities Shelf
Nuvectis Pharma files $200M mixed securities shelf
Nuvectis Pharma Receives Approval for Ciprocopan to Treat Paroxysmal Nocturnal Hemoglobinuria
Nuvectis Pharma announced that ciprocopan, a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China, or NMPA, for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria previously untreated with Complement inhibitors.
Major Averages Broadly Higher to Close Q2
The major averages had a broadly higher day to close out the second quarter as traders continue to monitor oil prices amid tensions in the Middle East. Despite geopolitical tensions, an oil-price shock earlier in the quarter, and persistent inflation concerns, the major indexes still notched one of their strongest quarterly performances in years.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Patrick Industriesand LCI Industriesin an all-stock mergerDigital Realtyin three data centers from Blackstonefor $7.8BAeroVironmentreportedand provided upbeat FY27 guidanceThe U.S. Supreme Court will hear Apple'sappeal challenging a contempt ruling in its long-running App Store dispute with Epic Games,Amazon Web Services (AMZN) isto embed AI Forward Deployed Engineers with customers2. WALL STREET CALLS:Deutsche Bank and RosenblattComcastto BuyOppenheimerGoldman Sachsand Morgan Stanleyto UnderperformBofAOlinto Underperform from BuyBMOReplimuneon higher chances of FDA approvalPiperBlockwith $100 target after analyst transfer3. AROUND THE WEB:Boeingand the Society of Professional Engineering Employees in Aerospace will begin formal contract talks ahead of October labor agreement expirations, Reuters reportsWilliamsis in advanced talks to acquire Momentum Midstream for about $5.5B from EnCap Flatrock Midstream, Bloomberg reportsFerrariand BMWare releasing new models using lightweight aluminum wiring, shifting away from using copper, Reuters saysComponent and supplier lists, and photos of iPhone 18 Pro models, are among files a ransomware group stole from Apple'sIndian supplier Tata, Reuters reportsWaymo'srobotaxis are no longer available on Uber'sapp in Phoenix, Arizona, TechCrunch says4. MOVERS:Abivaxincreased in New York after announcing resultsAevexgained after securing aRezolve AIwas higher in New York after its board of directorsSable Offshorewas lower after announcing a $100M stock andNuvectis Pharmafell after5. EARNINGS/GUIDANCE:Concentrixand cut its guidance for FY26General Millstoon July 1FactSettoon July 1Progress Softwaretoon June 30MSC Industrialtoon July 1INDEXES:The Dow rose 136.46, or 0.26%, to 52,319.20, the Nasdaq gained 393.57, or 1.52%, to 26,213.72, and the S&P 500 advanced 58.93, or 0.79%, to 7,499.36.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。